



# EMPA-KIDNEY

The study of heart and kidney protection with empagliflozin

## EMPA-KIDNEY Participant Newsletter

19 March 2020

To all **EMPA-KIDNEY** participants,

Thank you for all your time and effort in committing to the EMPA-KIDNEY trial. You are one of over **5000 people that have been screened**. Globally we now have over **3000 participants who have joined the randomised phase** of the trial, so we are nearly half way to the recruitment target of around 6000 participants. Below is a summary of some exciting milestones.

1st participant screened:	1 February 2019
1st participant randomised:	15 May 2019
5,000th participant screened:	6 March 2020
3,000th participant randomised:	17 March 2020

With your help, we will be able to answer the important clinical question of whether taking a single pill of empagliflozin every day prevents worsening of kidney disease or deaths from heart disease in people who have chronic kidney disease.

Study news will continue to be posted on

[www.empakidney.org](http://www.empakidney.org)

## Covid-19 (Coronavirus)

### Information for participants

The most recent challenge facing all of us is the Covid-19 pandemic. It has affected EMPA-KIDNEY participants and staff in many different ways. Some of you will not have been able to attend your randomisation visits, and we will be able to offer most of you the opportunity to be re-screened once the pandemic settles, so that you can still take part.

For those of you who have been randomised, you may have been asked to re-arrange study follow-up visits. We appreciate your flexibility during these difficult times.

If you are unable to attend a study clinic and are worried/concerned that you may run out of study treatment, please do not panic. It is generally safe to stop study treatment without the need to see your local doctor. However, if you are concerned please do contact your local doctor or study clinic. We will make arrangements to see you in a study clinic as soon as the Covid-19 situation allows. You can continue study treatment, but if you are admitted to hospital you may be asked to stop study treatment until your condition has stabilised. Please restart it when you are well, unless told otherwise by your doctors.

Please note that we are busy making arrangements so the study can follow you remotely via telephone. In the next few weeks, in certain regions, we aim to provide a service to courier study treatment to you. This is a temporary measure, and once Covid-19 has resolved, we will reinitiate your usual face-to-face trial visits.

You should continue to contact your local study team with study-related queries, but if you have any urgent study specific concerns and are unable to reach them, please do not hesitate to contact the central office on our freephone 0808 1644060 (UK) or 0044 808 1644060 (outside the UK).

